TY - JOUR
T1 - Nanotechnology-based strategies against SARS-CoV-2 variants
AU - Huang, Xiangang
AU - Kon, Edo
AU - Han, Xuexiang
AU - Zhang, Xingcai
AU - Kong, Na
AU - Mitchell, Michael J.
AU - Peer, Dan
AU - Tao, Wei
N1 - Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/10
Y1 - 2022/10
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 (COVID-19) pandemic. Nanotechnology has played a pivotal role in the fight against SARS-CoV-2 in various aspects, with the successful development of the two highly effective nanotechnology-based messenger RNA vaccines being the most profound. Despite the remarkable efficacy of mRNA vaccines against the original SARS-CoV-2 strain, hopes for quickly ending this pandemic have been dampened by the emerging SARS-CoV-2 variants, which have brought several new pandemic waves. Thus, novel strategies should be proposed to tackle the crisis presented by existing and emerging SARS-CoV-2 variants. Here, we discuss the SARS-CoV-2 variants from biological and immunological perspectives, and the rational design and development of novel and potential nanotechnology-based strategies to combat existing and possible future SARS-CoV-2 variants. The lessons learnt and design strategies developed from this battle against SARS-CoV-2 variants could also inspire innovation in the development of nanotechnology-based strategies for tackling other global infectious diseases and their future variants.
UR - http://www.scopus.com/inward/record.url?scp=85136491530&partnerID=8YFLogxK
U2 - 10.1038/s41565-022-01174-5
DO - 10.1038/s41565-022-01174-5
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35982317
AN - SCOPUS:85136491530
SN - 1748-3387
VL - 17
SP - 1027
EP - 1037
JO - Nature Nanotechnology
JF - Nature Nanotechnology
IS - 10
ER -
